IN THE SPOTLIGHT

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series

Clinical and structural insights into concurrent EGFR and MET exon 14 skipping mutations in NSCLC: a multi-center series

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

Sakditad Saowapa: EGFR TKI Resistance in NSCLC – Key Mechanisms

Sakditad Saowapa: EGFR TKI Resistance in NSCLC – Key Mechanisms

李醒亚教授:DESTINY-Lung05 研究再添获益新证,德曲妥珠单抗有望引领 HER2 变异 NSCLC 治疗迈向新纪元_腾讯新闻

李醒亚教授:DESTINY-Lung05 研究再添获益新证,德曲妥珠单抗有望引领 HER2 变异 NSCLC 治疗迈向新纪元_腾讯新闻

Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC

Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC

Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC